-transparent.png){kind=logo}
A prospectively controlled randomized clinical trial of adjuvant BCG immunotherapy in patients with stage 1B malignant melanoma (Clark's level 3--5) is described. The combination of intradermal and oral BCG allows approximation of the bacilli to any microscopic foci of residual disease. The trial was activated in May 1975 and to date 107 patients have been admitted to the trial, 49 patients being randomil entered patients, there have been five relapses of 49 patients in the treatment group and ten relapses of 58 patients in the control group. This encouraging trend is not yet statsitically significant at the 5% level (P = 0.17). If evaluable patients with Clark's level 3 and 4 lesions are assessed separately, there is a significant trend in favour of the immunotherapy group (P less than 0.05) with three relapses in the treatment group and ten relapses in the control group.
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
June 1983,
Journal of surgical oncology,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
June 1983,
Canadian Medical Association journal,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
January 1977,
Tumori,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
January 1977,
Developments in biological standardization,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
January 1981,
Archiv fur Geschwulstforschung,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
June 1985,
Indian journal of cancer,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
January 1983,
Cancer,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
July 1973,
Cancer,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
April 1979,
Cancer,
A H Paterson, and
D Willans, and
L M Jerry, and
T A McPherson
January 1991,
Dermatologica,
